Publications by authors named "Allen Cohn"

Claim this Profile
T
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.
Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li, Allen Cohn

Lancet Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Allen L Cohn, Marcia S Brose

J Immunother Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn

EClinicalMedicine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
Vicky Makker, Carol Aghajanian, Allen L Cohn, Margarita Romeo, Raquel Bratos

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi, Minetta C Liu, Eric A Klein, Oliver Venn, Earl Hubbell, Allen L Cohn

Cancer Cell· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony, Allen L Cohn

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
William D Tap, Arun S Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, Allen Lee Cohn

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, Matthew H Taylor, Allen Lee Cohn

Lancet Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Thomas Powles, Michael B Atkins, Bernard Escudier, Robert J Motzer, Brian I Rini, Allen Cohn

Eur Urol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander Rosemurgy, Sharona B Ross, Allen Cohn

J Pancreat Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infigratinib in patients with advanced cholangiocarcinoma with gene fusions/translocations: the PROOF 301 trial.
Shalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, Saeed Sadeghi, Ivan Borbath, Allen Cohn

Future Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen L Cohn

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Allen Cohn, Allen Cohn

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
David Fogelman, Antonio Cubillo, Pilar García-Alfonso, María Luisa Limón Mirón, John Nemunaitis, Allen Cohn

Cancer Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Hanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S Kasbari, Allen Lee Cohn

Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.
Allen Cohn, Michael A Morse, Bert O'Neil, Samuel Whiting, Claire Coeshott

J Immunother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.
Allen Lee Cohn, Takayuki Yoshino, Volker Heinemann, Radka Obermannova, György Bodoky

Cancer Chemother Pharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Robert C G Martin, Elizabeth Bruenderman, Allen Cohn, Bilal Piperdi, Rebecca Miksad

Am J Surg· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Johanna C Bendell, Howard Hochster, Lowell L Hart, Irfan Firdaus, Joseph R Mace, Allen L Cohn

Oncologist· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study.
Allen L Cohn, Bann-Mo Day, Sarang Abhyankar, Edward McKenna, Todd Riehl

Onco Targets Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Daniel W Bowles, Mark Kochenderfer, Allen Cohn, Lucas Sideris, Nghia Nguyen

Clin Colorectal Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.
Jean-Francois H Geschwind, Pierre M Gholam, Alec Goldenberg, Parvez Mantry, Robert C G Martin, Allen Cohn

Liver Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
William D Tap, Zev A Wainberg, Stephen P Anthony, Prabha N Ibrahim, Chao Zhang, Allen Lee Cohn

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis